This trial is testing immunotherapy drugs to treat patients with recurrent glioma who have a high number of mutations. The drugs may help the body's immune system attack the cancer and lower the chance of the cancer growing or spreading.
1 Primary · 3 Secondary · Reporting Duration: Up to 3 years
37 Total Participants · 1 Treatment Group
Primary Treatment: Ipilimumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: